Our research projects are funded by the following federal agencies:
|
K08 The development of a systematic approach to harness real-world evidence for the evaluation of medication safety and effectiveness in children, 2023 - 2028, NICHD
R01 Comparative safety of antibiotics for common bacterial infections during pregnancy, 2022-2027, NICHD R01 Safety of benzodiazepines and non-benzodiazepine sedative hypnotics in pregnancy, 2022-2027, NICHD R01 TreeScan to evaluate the safety of new drugs in pediatric populations, 2022-2027, NICHD R01 Active surveillance of the safety of antipsychotic medications in pregnancy, 2021-2026, NICHD |
|
R01 The comparative effectiveness and safety of pharmacotherapies for the treatment of opioid use disorder in pregnancy 2020-2029, NIDA
|
|
R03 Clinically recognized congenital cytomegalovirus infection and risk of long-term neurologic and non-neurologic complications: evidence from a nationwide cohort 2024-2025, NIAID
|
We also conduct research sponsored by industry partners (e.g., UCB, Takeda, Eli Lilly, GlaxoSmithKline).
Past Research Projects:
|
R01 In-utero exposure to psychotropic medications and the risk of neurodevelopmental disorder, 2018-2023, NIMH
K01 Improved methods to assess the comparative safety of new psychiatric medications, 2013-2018, NIMH R01 Comparative safety of commonly prescribed psychotropic drugs in pregnant women, 2014-2017, NIMH |
|
R01 Comparative safety of non-insulin agents in pregnant women with pre-gestational diabetes, 2019-2024, NICHD
R03 Ondansetron and risk of congenital malformations, 2017-2019, NICHD K08 Comparative safety and effectiveness of antihypertensives in pregnancy, 2013-2018, NICHD R21 Pregnancy registries nested in the international pooled health care databases, 2017-2019, NICHD R21 International pooling project to study the safety of drugs in pregnancy, 2017-2019, NICHD |
|
R01 The impact of prescription opioid use on pregnancy outcomes, 2017-2021, NIDA
|
|
R01 Comparative effectiveness and safety of depression treatments during pregnancy, 2009-2014, AHRQ
|
|
Developing the capability of using national Medicaid data for FDA post-marketing surveillance to assess medication safety during pregnancy, 2017-2019, FDA
|
